Évaluation d'une stratégie sélective de prescription des antagonistes de la glycoprotéine IIb/IIIa dans les syndromes coronariens aigus sans sus-décalage du segment ST

A strategy for glycoprotein IIb/IIIa inhibitors administration in non ST-segment elevation acute coronary syndrome restricted to 4 very high risk situations may be considered, without evidence for a loss of chance in intermediate risk patients, untreated although eligible for treatment according to the current guidelines.